Phlexglobal Partners with PRA Health Sciences to Create the Global TMF Center of Excellence
Phlexglobal has announced the successful creation and implementation of the Global TMF Center of Excellence with partner PRA Health Sciences.
Given the increasingly critical role played by the Trial Master File for supporting Good Clinical Practice (GCP), audit and inspection preparedness, and streamlined submissions, PRA conducted a comprehensive, multi-round review of TMF providers and chose Phlexglobal after a competitive bidding process. Building and implementation of PRA’s fit-for-purpose TMF Center of Excellence solution commenced shortly after the project award was given in early 2019.
With insights from the Global TMF Center of Excellence, PRA assists pharmaceutical and biotech sponsors in compliance and reducing risk by ensuring ongoing inspection-readiness with expert management of the quality, completeness, and timeliness of the Trial Master File. PhlexTMF technology supports this by providing effective sponsor oversight, streamlining collaboration and communication, and easily managing millions of documents across hundreds of studies.
Read the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
